Table 4.

Wearable Cardioverter-Defibrillator Therapies and Alarms.^*

Variable	Device Group (N = 1524)	Control Group (N = 778)	P Value
	no. of participants with event (%)
No. of total shocks			<0.001
0	1495 (98.1)	777 (99.9)
1	20 (1.3)	0
≥2	9 (0.6)	1 (0.1)
No. of appropriate shocks			0.008
0	1504 (98.7)	777 (99.9)
1	13 (0.9)	0
≥2	7 (0.5)	1 (0.1)
No. of inappropriate shocks			0.12
0	1515 (99.4)	778 (100)
1	7 (0.5)	0
≥2	2 (0.1)	0
No. of shocks aborted by pressing response button†			<0.001
0	1455 (95.5)	777 (99.9)
1	43 (2.8)	1 (0.1)
2–5	11 (0.7)	0
>5	15 (1.0)	0
No. of alarms indicating arrhythmia			<0.001
0	432 (28.3)	762 (97.9)
1	115 (7.5)	1 (0.1)
2–5	252 (16.5)	2 (0.3)
6–100	579 (38.0)	12 (1.5)
>100	146 (9.6)	1 (0.1)
No. of alarms indicating asystole			<0.001
0	1483 (97.3)	777 (99.9)
1	22 (1.4)‡	0
≥2	19 (1.2)‡	1 (0.1)

^*Shown are the numbers of participants who had an event over the entire 90-day period. The wearable cardioverter– defibrillator was used by 20 participants in the control group, who received the device outside the protocol. Percentages may not total 100 because of rounding. P values were not corrected for multiple comparisons.

^†This analysis included arrhythmia alarms lasting more than 30 seconds that were aborted when the participant pressed the shock-suppression button.

^‡Among 41 participants with an alarm indicating asystole, 6 events (all in the device group) were adjudicated as having had a true asystole event.